Medical research firm Natera surpassed Q2 revenue estimates with $413.35M and EPS of -$0.30.
Medical research firm Natera reported better-than-expected Q2 earnings, with EPS of -$0.30 and revenue of $413.35M, exceeding $343M estimates. The company's stock reached $114.57 during midday trading on May 15th. CEO Steven Leonard Chapman sold 6,779 shares, while institutional investors, like SG Americas Securities, have increased their stakes in Natera. Analysts have given mixed opinions on the stock, with ratings ranging from "hold" to "buy."
August 11, 2024
3 Articles